Information Provided By:
Fly News Breaks for May 12, 2015
NXTM
May 12, 2015 | 06:41 EDT
Piper Jaffray believes shares of NxStage Medical are attractive following the 13.5% pullback since last Wednesday's earnings report. Piper attributes to the weakness to concerns over the BAX blood tubing set contract worth $30M annually that expires at the end of the year and potential competition from Outset Medical. Piper sees no reason to "panic" over the contract and does not believe competition is likely in the next few years as Outset has yet to commence a home hemodialysis clinical trial for its Tablo dialysis machine. The firm reiterates an Overweight rating on NxStage with a $24 price target.
News For NXTM From the Last 2 Days
There are no results for your query NXTM